In ITP, mesenchymal stem cells (MSCs) are reported to be defective and show enhanced apoptosis [49], which results from miR-98-5p targeting insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) which is a crucial mediator in the IGF-2/PI3K/Akt pathway (Figure 3). This evidence concerns the gene IGF2 and autoimmune thrombocytopenic purpura.